SCHEMBL5469801

SCHEMBL5469801

CON1C(=O)Cc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.51
HPGD P15428 2/20 0.50
CASP3 P42574 2/20 0.46
CASP6 P55212 2/20 0.46
SENP8 Q96LD8 2/20 0.46
SENP7 Q9BQF6 2/20 0.46
SENP6 Q9GZR1 2/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
HTR7 P34969 3/20 0.41
DRD2 P14416 1/20 0.41
DRD5 P21918 1/20 0.41
DRD3 P35462 1/20 0.41
OPRM1 P35372 3/20 0.40
OPRK1 P41145 3/20 0.40
OPRL1 P41146 3/20 0.40
DDB1 Q16531 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8866530 0.86 HPGD (0.55) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL14995943 0.84 TUBB4A (0.41) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL30866418 0.83 POLB (0.47) NOTUMKMT2ATDP1DRD2DRD3
SCHEMBL10755793 0.81 NOTUM (0.51) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL7465147 0.80 NOTUM (0.47) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL6198012 0.80 MEN1 (0.47) NOTUMGAAKMT2AALDH1A1MEN1
SCHEMBL9954152 0.79 HPGD (0.49) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL10795075 0.79 NOTUM (0.46) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL28534576 0.79 NOTUM (0.58) NOTUMHPGDCASP3CASP6SENP8
SCHEMBL13495339 0.78 RNASEH1 (0.56) HPGDCASP3CASP6SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12553028-B2 Method to generate induced oligodendrocyte-lineage cells and treatment using such cells ACADEMIA SINICA (TW) 2026-02-17 US disclosed
US-20240316014-A1 METHOD FOR TREATING DEMYELINATING CONDITIONS ACADEMIA SINICA (TW) 2024-09-26 US disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-10751380-B2 Compound and method for treating spasms, inflammation and pain MEDEXY LLC 2020-08-25 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
EP-3558980-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2019-10-30 EP disclosed
US-20180193399-A1 COMPOUND AND METHOD FOR TREATING SPASMS, INFLAMMATION AND PAIN MEDEXY LLC 2018-07-12 US disclosed
WO-2018115275-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION IRBM SCIENCE PARK S.P.A. (IT) 2018-06-28 WO disclosed
US-20180169172-A1 COMPOUND AND METHOD FOR REDUCING APPETITE, FATIGUE AND PAIN KARIMAN ALEXANDER (US) 2018-06-21 US disclosed
US-8524898-B2 Proton acceptor iminium/carbocation-type coupling agents LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) 2013-09-03 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed
EP-1212318-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS Boehringer Ingelheim Pharma KG (DE) 2002-06-12 EP disclosed
WO-2001016130-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-08 WO disclosed
EP-0580502-B1 3-(Hydroxybenzylidenyl)-indoline-2-ones and pharmaceutical compositions containing them ADIR (FR) 1998-09-02 EP disclosed
EP-0646115-A1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 1995-04-05 EP disclosed
US-5382593-A Antioxidants or anticoagulants ADIR ET COMPAGNIE (FR) 1995-01-17 US disclosed
EP-0580502-A1 3-(Hydroxybenzylidenyl)-indoline-2-ones and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1994-01-26 EP disclosed
WO-1992017475-A1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES PFIZER INC. (US) 1992-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12553028-B2 Method to generate induced oligodendrocyte-lineage cells and treatment using such cells HDAC4, HDAC9, MYT1 NOTUM 4049/4885HPGD 1049/4885CASP3 1052/4885
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection NISCH, TK2, FDPS NOTUM 2310/4885HPGD 115/4885CASP3 708/4885
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION NISCH, TK2, FDPS NOTUM 2310/4885HPGD 115/4885CASP3 708/4885
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NOTUM 4145/4885HPGD 3379/4885CASP3 1035/4885
US-20240316014-A1 METHOD FOR TREATING DEMYELINATING CONDITIONS CDK5, PMP22, MYT1 NOTUM 2285/4885HPGD 2017/4885CASP3 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.